To assess whether cell types and transcriptional programs identified in tumor spheroids are present in other LGR5+ CRC models and patient tumors, we analyzed three patient-derived organoids (PDOs; O1–O3), two patient-derived xenografts (PDXs; X1, X2), and cells from three primary tumor samples (T1–T3) by droplet-based scRNA-seq [37,38] (Table 1). The gene discussed is LGR5; the disease is neoplasm.